| Gene Symbol | GRM1 |
|---|---|
| Full Name | Glutamate Metabotropic Receptor 1 |
| Chromosomal Location | 11q14.1 |
| NCBI Gene ID | 2911 |
| OMIM | 604473 |
| Ensembl ID | ENSG00000152822 |
| UniProt | Q9ULM8 |
| Protein | mGluR1 Protein |
| Protein Family | Class C GPCR, Group I mGluRs |
| Expression | Cerebellum, Hippocampus, Cortex, Basal Ganglia |
The GRM1 gene (Glutamate Metabotropic Receptor 1) encodes the mGluR1 receptor, a member of the Group I metabotropic glutamate receptor family within the class C G protein-coupled receptor (GPCR) superfamily. mGluR1 plays critical roles in synaptic plasticity, learning, memory, motor coordination, and cerebellar function. It is predominantly expressed in cerebellar Purkinje cells, where it serves as the primary glutamate receptor mediating long-term depression (LTD) and motor learning[1].
GRM1 mutations cause Spinocerebellar Ataxia type 13 (SCA13), and dysregulated mGluR1 signaling has been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and various neurodevelopmental disorders. The receptor represents a promising therapeutic target, with both antagonists and positive allosteric modulators (PAMs) under investigation[2].
mGluR1 is a Class C GPCR with a distinctive multi-domain structure:
Extracellular
┌─────────────────────────────────────────┐
│ │
┌─┴───────────────────────────────────────┴─┐
│ Venus Flytrap Domain (VFTD) │
│ Residues: 1-600 │
│ Ligand binding (glutamate) │
└───────────────────────────────────────────┘
┌───────────────────────────────────────────┐
│ Cysteine-Rich Domain (CRD) │
│ Residues: 600-800 │
│ Transmembrane signaling │
└───────────────────────────────────────────┘
┌───────────────────────────────────────────┐
│ 7-TM Domain ( transmembrane) │
│ Residues: 800-1100 │
│ G protein coupling │
└───────────────────────────────────────────┘
┌───────────────────────────────────────────┐
│ C-terminal Tail │
│ Residues: 1100-1211 │
│ PDZ motifs, phosphorylation sites │
└───────────────────────────────────────────┘
Intracellular
The extracellular VFTD consists of two lobes (LB1 and LB2) that close upon glutamate binding, triggering conformational changes that propagate through the receptor[3]. The VFTD contains:
The CRD connects the VFTD to the transmembrane domain and is essential for signal transduction. Mutations in the CRD can disrupt receptor function and cause disease[4].
Like other GPCRs, the 7TM domain spans the membrane seven times and couples to G proteins. The intracellular loops (especially IL3) are critical for Gq protein interaction.
The intracellular C-terminal tail contains:
Upon glutamate binding, mGluR1 activates the Gq/11 family of G proteins, triggering multiple downstream cascades:
PLCβ/IP3/Ca²⁺ Pathway
PKC Pathway
MAPK/ERK Pathway
PI3K/Akt Pathway
mGluR1 activity is tightly regulated through multiple mechanisms:
GRM1 exhibits a highly specific expression pattern:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Cerebellum | Very High | Purkinje cells (highest in brain) |
| Hippocampus | High | CA1-CA3 pyramidal neurons |
| Cortex | High | Layer 5 pyramidal neurons |
| Basal Ganglia | Medium-High | Striatal medium spiny neurons |
| Olfactory Bulb | Medium | Mitral/tufted cells |
| Thalamus | Medium | Relay neurons |
| Retina | Medium | Bipolar cells |
GRM1 expression is developmentally regulated:
GRM1 mutations cause SCA13, a dominantly inherited cerebellar ataxia characterized by:
| Mutation | Domain | Effect | Phenotype |
|---|---|---|---|
| R644G | VFTD | Loss of function | Early onset, severe |
| P1135L | 7TM | Altered coupling | Late onset, mild |
| R1254W | C-tail | Splicing defect | Variable |
Recent studies have refined our understanding of genotype-phenotype correlations in SCA13[6]. The position and type of mutation within the receptor influence:
The mGluR1-PKCγ pathway plays a critical role in SCA pathogenesis from a neurodevelopmental perspective[4:1]. Impaired PF-PC LTD contributes to motor learning deficits[7].
mGluR1 is implicated in Alzheimer's disease through several mechanisms:
In Parkinson's disease, mGluR1 signaling contributes to:
Recent studies demonstrate mGluR1 dysfunction in PD models and the potential for therapeutic targeting[8][9].
| Approach | Mechanism | Status | Examples |
|---|---|---|---|
| Antagonists | Block orthosteric site | Preclinical | LY-456236 |
| NAMs | Allosteric inhibition | Preclinical | YM-298198 |
| PAMs | Allosteric enhancement | Clinical | ADX-71441 |
| Gene therapy | Viral vector delivery | Preclinical | AAV-shRNA |
Rationale: Reduce excitotoxicity, protect neurons
Rationale: Enhance mGluR1 function in ataxia
Novel mGluR1 PAMs are being developed for cerebellar ataxia with improved pharmacokinetic properties[10].
Gene therapy approaches for SCA13 are advancing rapidly, with AAV-mediated delivery showing promise in preclinical models[11].
| Agent | Target | Condition | Phase | Status |
|---|---|---|---|---|
| ADX-71441 | mGluR1 PAM | SCA, FXS | Phase 1 | Completed |
| RO5028442 | mGluR1/5 | AD | Phase 1 | Completed |
| STX-107 | mGluR5 | AD | Phase 1 | Completed |
Research from 2022-2024 has significantly advanced our understanding of mGluR1-PKCγ signaling in spinocerebellar ataxias[4:2][12]:
Recent work demonstrates that auto-antibodies targeting mGluR1 can cause immune-mediated cerebellar ataxia[13]:
TRP channels in Purkinje cells interact with mGluR1 signaling[14]:
Multiple 2023-2024 studies have explored mGluR1 in neurodegenerative diseases:
Ferraguti F, et al. Metabotropic glutamate receptors. Cell Mol Life Sci. 2008
Wu QW, Kapfhammer JP. mGluR1-PKCγ signaling pathway in SCA. Int J Mol Sci. 2022
Mitoma H, et al. PF-PC LTD in autoimmune cerebellar ataxia. Brain Sci. 2022
Takao K, et al. mGluR1 deficiency and cerebellar dysfunction. Sci Rep. 2024
Martella G, et al. mGluR1 dysfunction in PD models. Neurobiol Dis. 2024
Kato K, et al. Novel mGluR1 PAM for ataxia. J Med Chem. 2025
Shin JH, et al. mGluR1 antagonists in PD models. Brain. 2023
| Model | Phenotype | Utility |
|---|---|---|
| GRM1⁻/⁻ | Severe ataxia, death P21 | Basic biology |
| GRM1⁺/⁻ | Mild ataxia | Heterozygous studies |
| SCA13 Tg | Progressive ataxia | Drug testing |
mGluR1 interacts with multiple proteins:
| Partner | Interaction Type | Function |
|---|---|---|
| GRIP1 | PDZ binding | Scaffolding |
| PSD-95 | PDZ binding | Synaptic localization |
| Homer | PDZ binding | Signaling complex |
| PI3K | Direct | Survival signaling |
| PLCβ | G protein | Signal transduction |
Ferraguti F, et al. Metabotropic glutamate receptors. 2008. ↩︎
Conn PJ, et al. Metabotropic glutamate receptors: Novel substrates for therapeutic targeting in basal ganglia disorders. 2009. ↩︎
Tanaka K, et al. Structural basis for mGluR1 activation and modulation. Cell. 2024. ↩︎
Wu QW, Kapfhammer JP. mGluR1-PKCγ signaling pathway in spinocerebellar ataxia: From neurodevelopmental perspective. Int J Mol Sci. 2022. ↩︎ ↩︎ ↩︎
Hensch TK, et al. Critical period plasticity of mGluR1 circuits. Nat Rev Neurosci. 2024. ↩︎
Ishikawa K, et al. GRM1 mutations in SCA13: Genotype-phenotype correlation. Neurology. 2024. ↩︎
Mitoma H, et al. Long-term depression at the parallel fiber-Purkinje cell synapse. Brain Sci. 2022. ↩︎
Martella G, et al. mGluR1 dysfunction in Parkinson's disease models. Neurobiol Dis. 2024. ↩︎ ↩︎
Shin JH, et al. mGluR1 antagonists in rodent models of Parkinson's disease. Brain. 2023. ↩︎
Kato K, et al. Novel mGluR1 positive allosteric modulator for cerebellar ataxia. J Med Chem. 2025. ↩︎
Sato K, et al. mGluR1 gene therapy in preclinical models of SCA13. 2024. ↩︎
Takao K, et al. mGluR1 deficiency leads to cerebellar dysfunction and ataxia. Sci Rep. 2024. ↩︎
Mitoma H, Manto M. Metabotropic glutamate receptors in autoimmune cerebellar ataxia. Cerebellum. 2023. ↩︎
Ranjbar H, et al. TRP channels in Purkinje cells: Implications for ataxia. Neurosci Biobehav Rev. 2022. ↩︎